Notably, NK-cell perturbations in MDS patients including reduction of activating NK receptors, such as NKp30, DNAM-1, and NKG2D, and impaired cytotoxicity, have already been reported12,15,30. This evidence concerns the gene KLRK1 and myelodysplastic syndrome.